Multicentre Phase III Study: Addition of Radiotherapy to Standard Medical Treatment for Stage IV NSCLC
The hypothesis for this study is that addition of a moderate dose of radiotherapy to the primary tumor and mediastinal nodes after three months of medical treatment could reduce the tumor burden, partly as an abscopal effect, and thereby improving quality of life and possible also prolonging survival for stage IV NSCLC.
• Histological or cytological confirmed non-small cell lung cancer (NSCLC)
• Stage IV disease
• Previously untreated disease (before first line treatment)
• No symptomatic brain metastases
• Performance status (WHO) 0-2
• FEV1 (forced expiratory volume one second) ≥ 1 L or \>40% of predicted
• Written informed consent
• Life expectancy ≥ 12 weeks
• Platelet count ≥ 100,00/mm3
• Hemoglobin ≥ 10 g/dl
• WBC (White blod cells) ≥ 3,000/mm3
• Kidney function allowing chemotherapy
• Patients scheduled for standard platinum based chemotherapy, chemo-immunotherapy or immunotherapy
• Willing and able to comply with study treatment